{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:29:11Z","timestamp":1760711351159},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s12029-024-01027-5","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T11:01:38Z","timestamp":1711969298000},"page":"638-651","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Aspirin in Patients with Viral Hepatitis: Systematic Review and Meta-Analysis of Observational Studies"],"prefix":"10.1007","volume":"55","author":[{"given":"Wentao","family":"Bian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenkai","family":"Bian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,1]]},"reference":[{"key":"1027_CR1","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","volume":"132","author":"El\u2013Serag HB, Rudolph KL,","year":"2007","unstructured":"El\u2013Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557\u201376. https:\/\/doi.org\/10.1053\/j.gastro.2007.04.061.","journal-title":"Gastroenterology"},{"key":"1027_CR2","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1158\/1055-9965.EPI-11-0643","volume":"20","author":"MM Center","year":"2011","unstructured":"Center MM, Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol Biomark Prev. 2011;20:2362\u20138. https:\/\/doi.org\/10.1158\/1055-9965.EPI-11-0643.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1027_CR3","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021535","volume":"5","author":"C-Y Liu","year":"2015","unstructured":"Liu C-Y, Chen K-F, Chen P-J. Treatment of liver cancer. Cold Spring Harb Perspect Med. 2015;5:a021535. https:\/\/doi.org\/10.1101\/cshperspect.a021535.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1027_CR4","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0140-6736(07)60747-8","volume":"369","author":"E Flossmann","year":"2007","unstructured":"Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies. The Lancet. 2007;369:1603\u201313. https:\/\/doi.org\/10.1016\/S0140-6736(07)60747-8.","journal-title":"The Lancet"},{"key":"1027_CR5","doi-asserted-by":"publisher","unstructured":"Dulai PS, Singh S, Marquez E, et al. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: Systematic review and network meta-analysis. BMJ 2016;i6188.\u00a0https:\/\/doi.org\/10.1136\/bmj.i6188.","DOI":"10.1136\/bmj.i6188"},{"key":"1027_CR6","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/S0140-6736(20)30366-4","volume":"395","author":"J Burn","year":"2020","unstructured":"Burn J, Sheth H, Elliott F, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: A double-blind, randomised, placebo-controlled trial. The Lancet. 2020;395:1855\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(20)30366-4.","journal-title":"The Lancet"},{"key":"1027_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12876-020-1158-y","volume":"20","author":"Y-H Liao","year":"2020","unstructured":"Liao Y-H, Hsu R-J, Wang T-H, et al. Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: A nationwide cohort study. BMC Gastroenterol. 2020;20:6. https:\/\/doi.org\/10.1186\/s12876-020-1158-y.","journal-title":"BMC Gastroenterol"},{"key":"1027_CR8","doi-asserted-by":"publisher","unstructured":"Jang H, Lee YB, Moon H, et al. Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. Hepatology hep. 2022;32380. https:\/\/doi.org\/10.1002\/hep.32380.","DOI":"10.1002\/hep.32380"},{"key":"1027_CR9","doi-asserted-by":"publisher","first-page":"758","DOI":"10.14309\/ajg.0000000000001725","volume":"117","author":"B Yun","year":"2022","unstructured":"Yun B, Ahn SH, Yoon JH, Kim BK. Clinical indication of aspirin associated with reduced risk of liver cancer in chronic hepatitis B: A nationwide cohort study. Am J Gastroenterol. 2022;117:758\u201368. https:\/\/doi.org\/10.14309\/ajg.0000000000001725.","journal-title":"Am J Gastroenterol"},{"key":"1027_CR10","doi-asserted-by":"publisher","first-page":"e00324","DOI":"10.14309\/ctg.0000000000000324","volume":"12","author":"VWK Hui","year":"2021","unstructured":"Hui VWK, Yip TCF, Wong VWS, et al. Aspirin reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B receiving oral nucleos(t)ide analog. Clin Transl Gastroenterol. 2021;12:e00324.\u00a0https:\/\/doi.org\/10.14309\/ctg.0000000000000324.","journal-title":"Clin Transl Gastroenterol"},{"key":"1027_CR11","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa1912035","volume":"382","author":"TG Simon","year":"2020","unstructured":"Simon TG, Duberg A-S, Aleman S, et al. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N Engl J Med. 2020;382:1018\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1912035.","journal-title":"N Engl J Med"},{"key":"1027_CR12","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF. Meta-analysis of observational studies in epidemiology A proposal for reporting. JAMA. 2000;283:2008. https:\/\/doi.org\/10.1001\/jama.283.15.2008.","journal-title":"JAMA"},{"key":"1027_CR13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/jamasurg.2021.0522","volume":"156","author":"BS Brooke","year":"2021","unstructured":"Brooke BS, Schwartz TA, Pawlik TM. MOOSE reporting guidelines for meta-analyses of observational studies. JAMA Surg. 2021;156:787. https:\/\/doi.org\/10.1001\/jamasurg.2021.0522.","journal-title":"JAMA Surg"},{"key":"1027_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603\u20135. https:\/\/doi.org\/10.1007\/s10654-010-9491-z.","journal-title":"Eur J Epidemiol"},{"key":"1027_CR15","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.3390\/cancers15112946","volume":"15","author":"C-H Lee","year":"2023","unstructured":"Lee C-H, Hsu C-Y, Yen T-H, et al. Daily aspirin reduced the incidence of hepatocellular carcinoma and overall mortality in patients with cirrhosis. Cancers. 2023;15:2946. https:\/\/doi.org\/10.3390\/cancers15112946.","journal-title":"Cancers"},{"key":"1027_CR16","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/apt.17643","volume":"58","author":"C Lee","year":"2023","unstructured":"Lee C, Lee YB, Moon H, et al. Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non-cirrhotic patients with chronic hepatitis B. Aliment Pharmacol Ther. 2023;58:704\u201314. https:\/\/doi.org\/10.1111\/apt.17643.","journal-title":"Aliment Pharmacol Ther"},{"key":"1027_CR17","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1038\/s41598-018-23343-0","volume":"8","author":"IC Hwang","year":"2018","unstructured":"Hwang IC, Chang J, Kim K, Park SM. Aspirin use and risk of hepatocellular carcinoma in a national cohort study of Korean adults. Sci Rep. 2018;8:4968. https:\/\/doi.org\/10.1038\/s41598-018-23343-0.","journal-title":"Sci Rep"},{"key":"1027_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12885-018-4292-y","volume":"18","author":"C-M Ho","year":"2018","unstructured":"Ho C-M, Lee C-H, Lee M-C, et al. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: A nationwide high-risk cohort study. BMC Cancer. 2018;18:401. https:\/\/doi.org\/10.1186\/s12885-018-4292-y.","journal-title":"BMC Cancer"},{"key":"1027_CR19","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1111\/liv.15011","volume":"41","author":"W Choi","year":"2021","unstructured":"Choi W, Kim HJ, Jo AJ, et al. Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study. Liver Int. 2021;41:2777\u201385. https:\/\/doi.org\/10.1111\/liv.15011.","journal-title":"Liver Int"},{"key":"1027_CR20","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/hep.32380","volume":"76","author":"H Jang","year":"2022","unstructured":"Jang H, Lee YB, Moon H, et al. Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. Hepatology. 2022;76:492\u2013501. https:\/\/doi.org\/10.1002\/hep.32380.","journal-title":"Hepatology"},{"key":"1027_CR21","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1002\/hep.29318","volume":"66","author":"M Lee","year":"2017","unstructured":"Lee M, Chung GE, Lee J, et al. Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. Hepatology. 2017;66:1556\u201369. https:\/\/doi.org\/10.1002\/hep.29318.","journal-title":"Hepatology"},{"key":"1027_CR22","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/jamainternmed.2018.8342","volume":"179","author":"T-Y Lee","year":"2019","unstructured":"Lee T-Y, Hsu Y-C, Tseng H-C, et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B. JAMA Intern Med. 2019;179:633. https:\/\/doi.org\/10.1001\/jamainternmed.2018.8342.","journal-title":"JAMA Intern Med"},{"key":"1027_CR23","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1016\/j.cgh.2020.04.036","volume":"18","author":"T-Y Lee","year":"2020","unstructured":"Lee T-Y, Hsu Y-C, Tseng H-C, et al. Association of daily aspirin therapy with hepatocellular carcinoma risk in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2020;18:2784-2792.e7. https:\/\/doi.org\/10.1016\/j.cgh.2020.04.036.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1027_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cld.2011.03.006","volume":"15","author":"KA McGlynn","year":"2011","unstructured":"McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: Present and future. Clin Liver Dis. 2011;15:223\u201343. https:\/\/doi.org\/10.1016\/j.cld.2011.03.006.","journal-title":"Clin Liver Dis"},{"key":"1027_CR25","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1196\/annals.1322.052","volume":"1028","author":"D Fodera","year":"2004","unstructured":"Fodera D. Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann N Y Acad Sci. 2004;1028:440\u20139. https:\/\/doi.org\/10.1196\/annals.1322.052.","journal-title":"Ann N Y Acad Sci"},{"key":"1027_CR26","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1053\/jhep.2003.50380","volume":"38","author":"J Leng","year":"2003","unstructured":"Leng J. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: Evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology. 2003;38:756\u201368. https:\/\/doi.org\/10.1053\/jhep.2003.50380.","journal-title":"Hepatology"},{"key":"1027_CR27","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1365-2893.2009.01117.x","volume":"16","author":"VTT Nguyen","year":"2009","unstructured":"Nguyen VTT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: Epidemiological characteristics and disease burden. J Viral Hepatitis. 2009;16:453\u201363. https:\/\/doi.org\/10.1111\/j.1365-2893.2009.01117.x.","journal-title":"J Viral Hepatitis"},{"key":"1027_CR28","doi-asserted-by":"crossref","unstructured":"Ganem D. Hepatitis B virus infection \u2014 Natural history and clinical consequences. N Engl J Med. 2004;12.","DOI":"10.1056\/NEJMra031087"},{"key":"1027_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1146\/annurev.pathol.1.110304.100230","volume":"1","author":"LG Guidotti","year":"2006","unstructured":"Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol Mech Dis. 2006;1:23\u201361. https:\/\/doi.org\/10.1146\/annurev.pathol.1.110304.100230.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"1027_CR30","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/nm1317","volume":"11","author":"M Iannacone","year":"2005","unstructured":"Iannacone M, Sitia G, Isogawa M, et al. Platelets mediate cytotoxic T lymphocyte\u2013induced liver damage. Nat Med. 2005;11:1167\u20139. https:\/\/doi.org\/10.1038\/nm1317.","journal-title":"Nat Med"},{"key":"1027_CR31","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1161\/01.ATV.0000145980.39477.a9","volume":"24","author":"M Cattaneo","year":"2004","unstructured":"Cattaneo M. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. ATVB. 2004;24:1980\u20137. https:\/\/doi.org\/10.1161\/01.ATV.0000145980.39477.a9.","journal-title":"ATVB"},{"key":"1027_CR32","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.3390\/cancers13071738","volume":"13","author":"H Zhang","year":"2021","unstructured":"Zhang H, Yang S, Wang J, Jiang Y. Blockade of AMPK-mediated cAMP\u2013PKA\u2013CREB\/ATF1 signaling synergizes with aspirin to inhibit hepatocellular carcinoma. Cancers. 2021;13:1738. https:\/\/doi.org\/10.3390\/cancers13071738.","journal-title":"Cancers"},{"key":"1027_CR33","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/hep.22215","volume":"47","author":"K Trujillo-Murillo","year":"2008","unstructured":"Trujillo-Murillo K, Rinc\u00f3n-S\u00e1nchez AR, Mart\u00ednez-Rodr\u00edguez H, et al. Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways. Hepatology. 2008;47:1462\u201372. https:\/\/doi.org\/10.1002\/hep.22215.","journal-title":"Hepatology"},{"key":"1027_CR34","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1007\/s00705-014-2201-5","volume":"159","author":"CP R\u00edos-Ibarra","year":"2014","unstructured":"R\u00edos-Ibarra CP, Lozano-Sepulveda S, Mu\u00f1oz-Espinosa L, et al. Downregulation of inducible nitric oxide synthase (iNOS) expression is implicated in the antiviral activity of acetylsalicylic acid in HCV-expressing cells. Arch Virol. 2014;159:3321\u20138. https:\/\/doi.org\/10.1007\/s00705-014-2201-5.","journal-title":"Arch Virol"},{"key":"1027_CR35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/jvh.12446","volume":"23","author":"P Yin","year":"2016","unstructured":"Yin P, Zhang L. Aspirin inhibits hepatitis C virus entry by downregulating claudin-1. J Viral Hepat. 2016;23:62\u20134. https:\/\/doi.org\/10.1111\/jvh.12446.","journal-title":"J Viral Hepat"},{"issue":"-","key":"1027_CR36","doi-asserted-by":"publisher","first-page":"-","DOI":"10.1073\/pnas.1209182109","volume":"109","author":"G Sitia","year":"2012","unstructured":"Sitia G, Aiolfi R, Di Lucia P, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA. 2012;109. https:\/\/doi.org\/10.1073\/pnas.1209182109.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1027_CR37","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1158\/0008-5472.CAN-21-0758","volume":"81","author":"E Ricciotti","year":"2021","unstructured":"Ricciotti E, Wangensteen KJ, FitzGerald GA. Aspirin in hepatocellular carcinoma. Can Res. 2021;81:3751\u201361. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-0758.","journal-title":"Can Res"},{"key":"1027_CR38","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/ajg.2010.475","volume":"106","author":"H-F Chiu","year":"2011","unstructured":"Chiu H-F, Ho S-C, Chen C-C, Yang C-Y. Statin use and the risk of liver cancer: A population-based case\u2013control study. Am J Gastroenterol. 2011;106:894\u20138. https:\/\/doi.org\/10.1038\/ajg.2010.475.","journal-title":"Am J Gastroenterol"},{"key":"1027_CR39","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/ijc.30506","volume":"140","author":"G Kim","year":"2017","unstructured":"Kim G, Jang S-Y, Han E, et al. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study: Statin use and the risk of HCC in DM patients. Int J Cancer. 2017;140:798\u2013806. https:\/\/doi.org\/10.1002\/ijc.30506.","journal-title":"Int J Cancer"},{"key":"1027_CR40","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/jgh.12503","volume":"29","author":"SJ Lee","year":"2014","unstructured":"Lee SJ, Hwang JW, Yim H, et al. Synergistic effect of simvastatin plus NS398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line: Anticancer effect of simvastatin-NS398. J Gastroenterol Hepatol. 2014;29:1299\u2013307. https:\/\/doi.org\/10.1111\/jgh.12503.","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01027-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-024-01027-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01027-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T15:21:10Z","timestamp":1718810470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-024-01027-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1027"],"URL":"https:\/\/doi.org\/10.1007\/s12029-024-01027-5","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,1]]},"assertion":[{"value":"5 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}